The prevalence of FV Hong Kong in patients with thrombotic disorders in South China
Related Experiment Video
Updated: Sep 9, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Lixuan Chen1, Rui Tuo2,3, Qinglin Mo4
1Department of Hematology, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, 518067, Guangdong, China.
To investigate the prevalence of FV Hong Kong(p.Arg306Gly) variant in patients with thrombotic disorders in South China, and to explore the association between FV Hong Kong and thrombosis according to genotype and clinical manifestations of the patients. A total of 367 patients with thrombotic disorders and 555 healthy volunteers in South China were screened by exon sequencing to identify FV Hong Kong variant carriers. Acquired risk factors for thrombosis of all subjects were also recorded. Among 367 thrombosis patients, 10 (2.72%) carried heterozygous FV Hong Kong mutations. In contrast, 9 of 555 healthy controls (1.62%) harbored the heterozygous mutation. There is no significant differences in the prevalence rate between patients and healthy controls. Among patients with the FV Hong Kong mutation, 90% exhibited concurrent predisposing factors. The FV Hong Kong variant demonstrates a high prevalence in the South Chinese population, with a similar rate in thrombosis patients and healthy population. The variant, when co-occurring with genetic or acquired risk factors, may synergistically elevate thrombotic risk. Further investigations are warranted to elucidate the clinical implications in thrombotic disorders.
To investigate the prevalence of FV Hong Kong(p.Arg306Gly) variant in patients with thrombotic disorders in South China, and to explore the association between FV Hong Kong and thrombosis according to genotype and clinical manifestations of the patients. A total of 367 patients with thrombotic disorders and 555 healthy volunteers in South China were screened by exon sequencing to identify FV Hong Kong variant carriers. Acquired risk factors for thrombosis of all subjects were also recorded. Among 367 thrombosis patients, 10 (2.72%) carried heterozygous FV Hong Kong mutations. In contrast, 9 of 555 healthy controls (1.62%) harbored the heterozygous mutation. There is no significant differences in the prevalence rate between patients and healthy controls. Among patients with the FV Hong Kong mutation, 90% exhibited concurrent predisposing factors. The FV Hong Kong variant demonstrates a high prevalence in the South Chinese population, with a similar rate in thrombosis patients and healthy population. The variant, when co-occurring with genetic or acquired risk factors, may synergistically elevate thrombotic risk. Further investigations are warranted to elucidate the clinical implications in thrombotic disorders.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care
Single Nucleotide Polymorphisms-SNPs
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

